RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Titel:
RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
Auteur:
Nishio, Makoto Paz-Ares, Luis Reck, Martin Nakagawa, Kazuhiko Garon, Edward B. Popat, Sanjay Ceccarelli, Matteo Graham, Hillary T. Visseren-Grul, Carla Novello, Silvia